Company intelligence / Profile preview

Avolynt

Research Triangle Park, North Carolina, United Statesavolynt.com ↗

Ownership: Private
Employees: ~49
Development stage: Phase 2

Overview

Positive topline data from Phase 2b BRID study of remogliflozin etabonate showed statistically significant decreases in placebo-adjusted HbA1c ranging from 0.44% to 0.6%, decreases in body weight, fasting plasma glucose, and blood pressure. NAFLD fibrosis scores were also decreased from baseline in two of three treatment groups.[5]

Therapeutic areas: GastroenterologyEndocrinologyMetabolic DisordersRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

remogliflozin etabonate

Phase 2

Indications: Type 2 diabetes

Partnerships

Kissei Pharmaceutical Co., Ltd. (Japan)Libbs Farmaceutica (Brazil)

Beyond the preview

Go deeper on Avolynt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avolynt.

Explore the full profile